{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:51:13Z","timestamp":1791143473297,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[2007,2,23]],"date-time":"2007-02-23T00:00:00Z","timestamp":1172188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,23]],"date-time":"2007-02-23T00:00:00Z","timestamp":1172188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1007\/s10792-007-9040-2","type":"journal-article","created":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T18:20:19Z","timestamp":1172168419000},"page":"211-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Interferon-\u03b12a and Vogt\u2013Koyanagi\u2013Harada disease: a double-edged sword?"],"prefix":"10.1007","volume":"27","author":[{"given":"Valerie","family":"Touitou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Sene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fardeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi-Huong-Du","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Duhaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Piette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc","family":"LeHoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,23]]},"reference":[{"key":"9040_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","volume":"8","author":"B Wechsler","year":"2000","unstructured":"Wechsler B, Bodaghi B, Huong DL et al (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet\u2019s disease. Ocul Immunol Inflamm 8:293\u2013301","journal-title":"Ocul Immunol Inflamm"},{"key":"9040_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","volume":"75","author":"P Pivetti-Pezzi","year":"1997","unstructured":"Pivetti-Pezzi P, Accorinti M, Pirraglia MP et al (1997) Interferon alpha for ocular Behcet\u2019s disease. Acta Ophthalmol Scand 75:720\u2013722","journal-title":"Acta Ophthalmol Scand"},{"key":"9040_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1076\/0927-3948(200006)8:2;1-0;FT085","volume":"8","author":"AA Okada","year":"2000","unstructured":"Okada AA (2000) Drug therapy in Behcet\u2019s disease. Ocul Immunol Inflamm 8:85\u201391 (in press)","journal-title":"Ocul Immunol Inflamm"},{"key":"9040_CR4","doi-asserted-by":"crossref","unstructured":"Bodaghi B, Gendron G, Wechsler B et al (2006) Efficacy of interferon alpha in the treatment of refractory and sight-threatening uveitis : a retrospective monocentric study of 45 patients. Br J Ophthalmol (in press)","DOI":"10.1136\/bjo.2006.101550"},{"key":"9040_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","volume":"26","author":"CM Deuter","year":"2006","unstructured":"Deuter CM, Koetter I, Guenaydin I et al (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26:786\u2013791","journal-title":"Retina"},{"key":"9040_CR6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.ajo.2005.04.025","volume":"140","author":"E Brasnu","year":"2005","unstructured":"Brasnu E, Wechsler B, Bron A et al (2005) Efficacy of interferon-alpha for the treatment of Kaposi\u2019s sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 140:746\u2013748","journal-title":"Am J Ophthalmol"},{"key":"9040_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1076\/ocii.10.4.299.15588","volume":"10","author":"T Matsuo","year":"2002","unstructured":"Matsuo T, Takabatake R (2002) Multiple sclerosis-like disease secondary to alpha interferon. Ocul Immunol Inflamm 10:299\u2013304","journal-title":"Ocul Immunol Inflamm"},{"key":"9040_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0168-8278(02)00243-X","volume":"37","author":"G Perlemuter","year":"2002","unstructured":"Perlemuter G, Bodaghi B, Le Hoang P et al (2002) Visual loss during interferon-alpha therapy in hepatitis C virus infection. J Hepatol 37:701\u2013702","journal-title":"J Hepatol"},{"key":"9040_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(94)90031-0","volume":"343","author":"H Yamada","year":"1994","unstructured":"Yamada H, Mizobuchi K, Isogai Y (1994) Acute onset of ocular complications with interferon. Lancet 343:914","journal-title":"Lancet"},{"key":"9040_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1046\/j.1365-2893.2003.00456.x","volume":"10","author":"DL Sylvestre","year":"2003","unstructured":"Sylvestre DL, Disston AR, Bui DP (2003) Vogt\u2013Koyanagi\u2013Harada disease associated with interferon alpha-2b\/ribavirin combination therapy. J Viral Hepat 10:467\u2013470","journal-title":"J Viral Hepat"},{"key":"9040_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ajo.2005.06.020","volume":"140","author":"V Touitou","year":"2005","unstructured":"Touitou V, Bodaghi B, Cassoux N et al (2005) Vogt\u2013Koyanagi\u2013Harada disease in patients with chronic hepatitis C. Am J Ophthalmol 140:949\u2013952","journal-title":"Am J Ophthalmol"},{"key":"9040_CR12","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1007\/s00535-004-1452-4","volume":"39","author":"A Kasahara","year":"2004","unstructured":"Kasahara A, Hiraide A, Tomita N et al (2004) Vogt\u2013Koyanagi\u2013Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol 39:1106\u20131109","journal-title":"J Gastroenterol"},{"issue":"Suppl 4","key":"9040_CR13","doi-asserted-by":"publisher","first-page":"449s","DOI":"10.1016\/S0248-8663(02)00659-8","volume":"23","author":"P Arnaud","year":"2002","unstructured":"Arnaud P (2002) [The interferons: pharmacology, mechanism of action, tolerance and side effects]. Rev Med Interne 23(Suppl 4):449s\u2013458s","journal-title":"Rev Med Interne"},{"key":"9040_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1089\/jir.2006.26.462","volume":"26","author":"C Sanda","year":"2006","unstructured":"Sanda C, Weitzel P, Tsukahara T et al (2006) Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res 26:462\u2013472","journal-title":"J Interferon Cytokine Res"},{"key":"9040_CR15","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/intimm\/10.12.1917","volume":"10","author":"AA Okada","year":"1998","unstructured":"Okada AA, Keino H, Suzuki J et al (1998) Kinetics of intraocular cytokines in the suppression of experimental autoimmune uveoretinitis by type I IFN. Int Immunol 10:1917\u20131922","journal-title":"Int Immunol"},{"key":"9040_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1076\/ocii.6.4.215.4024","volume":"6","author":"AA Okada","year":"1998","unstructured":"Okada AA, Keino H, Fukai T et al (1998) Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6:215\u2013226","journal-title":"Ocul Immunol Inflamm"},{"key":"9040_CR17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/0-306-48382-3_108","volume":"528","author":"N Stubiger","year":"2003","unstructured":"Stubiger N, Crane IJ, Kotter I et al (2003) Interferon alpha 2a in IRPB-derived peptide-induced EAU\u2013part I. Adv Exp Med Biol 528:537\u2013540","journal-title":"Adv Exp Med Biol"},{"key":"9040_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/0-306-48382-3_107","volume":"528","author":"M Treusch","year":"2003","unstructured":"Treusch M, Stubiger N, Vonthein R et al (2003) Influence of interferon-alpha on lymphocyte subpopulations in Behcet\u2019s disease. Adv Exp Med Biol 528:533\u2013535","journal-title":"Adv Exp Med Biol"},{"key":"9040_CR19","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/rheumatology\/keh311","volume":"43","author":"M Treusch","year":"2004","unstructured":"Treusch M, Vonthein R, Baur M et al (2004) Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet\u2019s disease. Rheumatology (Oxford) 43:1275\u20131282","journal-title":"Rheumatology (Oxford)"},{"key":"9040_CR20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/0-306-48382-3_102","volume":"528","author":"I Kotter","year":"2003","unstructured":"Kotter I, Gunaydin I, Treusch M et al (2003) The use of interferon-alpha in Behcet\u2019s disease\u2013review of the literature and possible mechanisms of action. Adv Exp Med Biol 528:503\u2013509","journal-title":"Adv Exp Med Biol"},{"key":"9040_CR21","first-page":"55","volume":"51","author":"R Pellicano","year":"2005","unstructured":"Pellicano R, Smedile A, Peyre S et al (2005) Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist\u2019s view. Minerva Gastroenterol Dietol 51:55\u201361","journal-title":"Minerva Gastroenterol Dietol"},{"key":"9040_CR22","first-page":"451","volume":"7","author":"C Selmi","year":"2006","unstructured":"Selmi C, Lleo A, Zuin M et al (2006) Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 7:451\u2013456","journal-title":"Curr Opin Investig Drugs"},{"key":"9040_CR23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0002-9394(14)71964-6","volume":"122","author":"Y Oshima","year":"1996","unstructured":"Oshima Y, Harino S, Hara Y et al (1996) Indocyanine green angiographic findings in Vogt\u2013Koyanagi\u2013Harada disease. Am J Ophthalmol 122:58\u201366","journal-title":"Am J Ophthalmol"},{"key":"9040_CR24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/112067219700700208","volume":"7","author":"T Harada","year":"1997","unstructured":"Harada T, Kanbara Y, Takeuchi T et al (1997) Exploration of Vogt\u2013Koyanagi\u2013Harada syndrome by infrared choroidal angiography with indocyanine green. Eur J Ophthalmol 7:163\u2013170","journal-title":"Eur J Ophthalmol"},{"key":"9040_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0161-6420(00)00428-0","volume":"108","author":"N Bouchenaki","year":"2001","unstructured":"Bouchenaki N, Herbort CP (2001) The contribution of indocyanine green angiography to the appraisal and management of Vogt\u2013Koyanagi\u2013Harada disease. Ophthalmology 108:54\u201364","journal-title":"Ophthalmology"},{"key":"9040_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0002-9343(02)01102-6","volume":"112","author":"R Gupta","year":"2002","unstructured":"Gupta R, Singh S, Tang R et al (2002) Anterior ischemic optic neuropathy caused by interferon alpha therapy. Am J Med 112:683\u2013684","journal-title":"Am J Med"},{"key":"9040_CR27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00041327-200312000-00003","volume":"23","author":"Y Vardizer","year":"2003","unstructured":"Vardizer Y, Linhart Y, Loewenstein A et al (2003) Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol 23:256\u2013259","journal-title":"J Neuroophthalmol"},{"key":"9040_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000027450","volume":"213","author":"F Norcia","year":"1999","unstructured":"Norcia F, Di Maria A, Prandini F et al (1999) Natural interferon therapy: optic nerve ischemic damage? Ophthalmologica 213:339\u2013340","journal-title":"Ophthalmologica"},{"key":"9040_CR29","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/archopht.1995.01100080093034","volume":"113","author":"VA Purvin","year":"1995","unstructured":"Purvin VA (1995) Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 113:1041\u20131044","journal-title":"Arch Ophthalmol"},{"key":"9040_CR30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJMc052880","volume":"354","author":"AA van der Eijk","year":"2006","unstructured":"van der Eijk AA, Vrolijk JM, Haagmans BL (2006) Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N Engl J Med 354:1323\u20131324","journal-title":"N Engl J Med"},{"key":"9040_CR31","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-199550050-00007","volume":"50","author":"M Haria","year":"1995","unstructured":"Haria M, Benfield P (1995) Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 50:873\u2013896","journal-title":"Drugs"},{"key":"9040_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0168-8278(98)80309-7","volume":"28","author":"V Leroy","year":"1998","unstructured":"Leroy V, Baud M, de Traversay C et al (1998) Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 28:375\u2013381","journal-title":"J Hepatol"},{"key":"9040_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0022-510X(99)00185-9","volume":"168","author":"G Antonelli","year":"1999","unstructured":"Antonelli G, Simeoni E, Bagnato F et al (1999) Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 168:131\u2013136","journal-title":"J Neurol Sci"},{"key":"9040_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1089\/jir.1998.18.345","volume":"18","author":"G Antonelli","year":"1998","unstructured":"Antonelli G, Bagnato F, Pozzilli C et al (1998) Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res 18:345\u2013350","journal-title":"J Interferon Cytokine Res"},{"key":"9040_CR35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1089\/10799900252952208","volume":"22","author":"C Ross","year":"2002","unstructured":"Ross C, Engler CB, Sander B et al (2002) IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a. J Interferon Cytokine Res 22:421\u2013426","journal-title":"J Interferon Cytokine Res"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-007-9040-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-007-9040-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-007-9040-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-007-9040-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T01:58:11Z","timestamp":1652839091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-007-9040-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,23]]},"references-count":35,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["9040"],"URL":"https:\/\/doi.org\/10.1007\/s10792-007-9040-2","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,23]]},"assertion":[{"value":"14 December 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}